Estimated Vaccination Coverage With Selected Vaccines Among Adolescents Aged 13-17* Years by Age at Interview
-- National Immunization Survey-Teen, United States, 2008
	Age at Interview (years)
	13	14	15	16	17		2008
	n = 3,455	n = 3,641	n = 3,666	n = 3,731	n = 3,342		n = 17,835
Vaccines	% (95% CI)†	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)		% (95% CI)
MMR§  ≥ 2 doses	90.3 (88.0-92.2)	91.8 (89.8-93.4)	90.1 (88.1-91.8)	86.2 (83.7-88.4)	88.1 (86.1-89.9)		89.3 (88.4-90.2)
Hepatitis B ≥ 3 doses	92.8 (91.1-94.1)	93.1 (91.5-94.3)	89.6 (87.0-91.7)	81.5 (78.6-84.1)	82.9 (80.7-84.8)		87.9 (86.9-88.8)
Varicella
History of varicella   disease¶	42.3 (39.2-45.5)	50.1 (46.9-53.3)	62.8 (59.5-66.0)	68.2 (65.1-71.2)	74.8 (71.3-78.1)		59.8 (58.4-61.3)
≥ 1 dose vaccine if had no history of disease	89.6 (87.1-91.6)	85.2 (81.6-88.3)	80.2 (75.2-84.4)	76.5 (71.8-80.6)	68.2 (61.7-74.1)		81.9 (80.2-83.6)
≥ 2 doses vaccine if had no history of disease	40.5 (36.4-44.8)	34.5 (30.1-39.1)	34.2 (29.1-39.7)	28.1 (22.9-33.9)	26.9 (18.9-36.7)		34.1 (31.8-36.5)
History of disease or received ≥ 1 dose varicella vaccination	94.0 (92.5-95.2)	92.6 (90.7-94.2)	92.6 (90.5-94.3)	92.5 (91.0-93.8)	92.0 (90.5-93.3)		92.7 (92.0-93.4)
Td or Tdap since age 10 years**
≥ 1 dose Td or Tdap	64.1 (61.0-67.2)	69.7 (66.5-72.7)	77.7 (75.2-80.0)	74.8 (71.9-77.5)	73.7 (70.7-76.6)		72.2 (70.8-73.4)
≥ 1 dose Tdap	51.9 (48.7-55.1)	47.3 (44.0-50.5)	41.5 (38.1-44.9)	35.1 (32.1-38.1)	28.7 (25.5-32.1)		40.8 (39.3-42.2)
MCV4§§  ≥1 dose	42.0 (38.8-45.1)	43.0 (39.9-46.3)	46.4 (43.0-49.7)	40.5 (37.4-43.6)	36.7 (33.5-40.0)		41.8 (40.3-43.2)
HPV4¶¶
≥ 1 dose	35.2 (31.1-39.6)	33.8 (29.5-38.3)	42.2 (37.5-47.2)	35.7 (31.7-39.9)	38.5 (33.3-43.9)		37.2 (35.1-39.3)
≥ 3 doses	14.5 (11.9-17.5)	16.6 (13.5-20.2)	18.5 (15.5-21.8)	18.8 (15.6-22.4)	20.9 (16.3-26.3)		17.9 (16.3-19.6)
* Adolescents in the 2008 NIS-Teen were born during January 1990-February 1996.
†State estimate presented as point estimate (%) ± 95% confidence interval (CI).
§ Measles, mumps, and rubella vaccine.
¶  By parent/guardian report or provider records.
** Includes percentages receiving tetanus and diptheria toxoid vaccine (Td), tetanus toxoid, reduced diptheria toxid, and acellular pertussis (Tdap), or tetanus-unknown type vaccine.
§§ Includes percentages receiving meningococcal conjugate vaccine (MCV4) or meningococcal-unknown type vaccine.
¶¶  Quadrivalent human papillomavirus vaccine. Percentages reported among females only (n=8,607); HPV4 vaccine is not recommended for males.